(Q37756594)

22 August 2017

1 reference

title

Bisphosphonates in the treatment of metabolic bone diseases (English)

1 reference

22 August 2017

author name string

Henrique Pierotti Arantes

series ordinal

1

1 reference

22 August 2017

André Gonçalves da Silva

series ordinal

2

1 reference

22 August 2017

Marise Lazaretti-Castro

series ordinal

3

1 reference

22 August 2017

publication date

1 March 2010

1 reference

Arquivos Brasileiros de Endocrinologia e Metabologia

22 August 2017

published in

1 reference

22 August 2017

volume

54

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

206-212

1 reference

Bone quality--the material and structural basis of bone strength and fragility

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Bisphosphonates: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Bisphosphonates: a review of their pharmacokinetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Studies of the oral bioavailability of alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Mechanism of action of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Quality of life in patients with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

The impact of compliance with osteoporosis therapy on fracture rates in actual practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Tolerability and compliance with risedronate in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Safety of bisphosphonates in the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Renal Failure with the Use of Zoledronic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Osteoporosis after solid organ and bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Severely suppressed bone turnover: a potential complication of alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Seven years of treatment with risedronate in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200017

10.1590/S0004-27302010000200017

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference